Pharmaceutical News

RSS

Findings raise hope for new oral anticoagulants to treat patients with atrial fibrillation

Approximately one in two patients with atrial fibrillation (Afib) do not optimally reduce their risk of stroke or bleeding when treated with the most widely prescribed oral-anticoagulant therapy, according to a study published online in Circulation, the journal of the American Heart Association.

From Quest Diagnostics 5 Feb 2014

Scientists engineered microchip coated with blood vessel cells to study cardiovascular nanomedicine

Designing nanomedicine to combat diseases is a hot area of scientific research, primarily for treating cancer, but very little is known in the context of atherosclerotic disease.

5 Feb 2014

UCSF-led study gathers data on safety, tolerability of purified cannabinoid for children with epilepsy

A new international multi-center study led by researchers from UCSF Benioff Children's Hospital is the first to evaluate whether purified cannabinoid is effective in treating severe forms of childhood epilepsy that do not respond to standard antiepileptic drugs.

5 Feb 2014

95% of adults die annually from vaccine preventable diseases

While adults make up 95 percent of those who die annually from vaccine preventable diseases, a new study from the University of Colorado School of Medicine shows their vaccination rates remain stubbornly low, representing a growing public health concern.

5 Feb 2014

New drug treatment effective against chronic pain caused by nerve damage post shingles

A new drug treatment has been found to be effective against chronic pain caused by nerve damage, also known as neuropathic pain, in patients who have had shingles.

5 Feb 2014

Researchers identify key step to prevent liver failure resulting from painkiller overdose

University of Adelaide researchers have identified a key step for the future prevention of liver failure resulting from taking too much of the everyday painkiller paracetamol (also known as acetaminophen).

5 Feb 2014

Blood disorder medicines could be used for treating stomach and bowel cancer

Stomach and bowel cancer, two of the most common cancers worldwide, could be treated with a class of medicines that are currently used to treat a blood disorder, a Melbourne research team has discovered.

5 Feb 2014

MORE intervention reduces pain and opioid misuse

With nearly one-third of Americans suffering from chronic pain, prescription opioid painkillers have become the leading form of treatment for this debilitating condition. Unfortunately, misuse of prescription opioids can lead to serious side effects-including death by overdose.

5 Feb 2014

Healthcare experts propose concrete steps for managing shortages of life-saving drugs

A group of prominent healthcare experts including bioethicists, pharmacists, policymakers and cancer specialists have proposed concrete steps for preventing and managing a nightmare scenario that is becoming all too common: shortages of life-saving drugs.

4 Feb 2014

Edison's vatiquinone receives Orphan Status for treatment of Friedreich's ataxia

Edison Pharmaceuticals today announced that the US Food and Drug Administration has granted Orphan Status to vatiquinone for the treatment of Friedreich's ataxia.

4 Feb 2014

Discovery may have implications for HIV vaccine research

NIH scientists have discovered a mechanism involved in stabilizing key HIV proteins and thereby concealing sites where some of the most powerful HIV neutralizing antibodies bind, findings with potential implications for HIV vaccine research.

4 Feb 2014

Patient controlled analgesia not equivalent to epidural analgesia for pain relief during labor

In a study to be presented on Feb. 7 at 1:30 p.m. CST, at the Society for Maternal-Fetal Medicine's annual meeting, The Pregnancy Meeting-, in New Orleans, researchers will report findings which suggest remifentanil patient controlled analgesia is not equivalent to epidural analgesia for pain, pain appreciation scores, and overall satisfaction in women who request for pain relief during labor.

4 Feb 2014

FDA grants Breakthrough Therapy designation to GSK's Promacta/Revolade for treatment of cytopenias

Ligand Pharmaceuticals Incorporated today announced that the U.S. Food and Drug Administration has granted its partner GlaxoSmithKline plc Breakthrough Therapy designation for Promacta/Revolade (eltrombopag) for the treatment of cytopenias in patients with severe aplastic anemia (SAA) who have had insufficient response to immunosuppressive therapy.

3 Feb 2014

Addressing antibiotic resistance: an interview with Professor Otto Cars, Uppsala University, Sweden

Antibiotic resistance is a consequence of antibiotic use. Bacteria adapt to the threat of antibiotics using mechanisms to overcome the drug. These bacteria, which we call resistant bacteria, then survive.

3 Feb 2014

Teen girls' beliefs regarding HPV vaccine not linked to subsequent sexual behaviors

A new study may alleviate concerns that the human papillomavirus (HPV) vaccine leads to either the initiation of sex or unsafe sexual behaviors among teenage girls and young women.

3 Feb 2014

Mylan launches trastuzumab biosimilar for treatment of HER2-positive metastatic breast cancer

Mylan Inc. (Nasdaq: MYL), one of the world's leading generic and specialty pharmaceutical companies, today announced that its subsidiary, Mylan Pharmaceuticals Private Limited, has launched the world's first trastuzumab biosimilar in India.

3 Feb 2014

Onset Dermatologics announces nationwide availability of Tretin-X Cream 0.075%

Onset Dermatologics, LLC, a leader in developing and commercializing prescription products for improving skin health, announced the nationwide availability of Tretin-X (tretinoin, USP) Cream 0.075%. Tretin-X Cream is a prescription product for the topical treatment of acne.

31 Jan 2014

New study reveals way to combat drug-resistant tumors

Cancer drugs that recruit antibodies from the body's own immune system to help kill tumors have shown much promise in treating several types of cancer. However, after initial success, the tumors often return.

31 Jan 2014

VIB and CD3 sign agreement with AstraZeneca for development of novel MALT1 inhibitors

VIB and CD3 (KU Leuven) today announced the signing of a license and collaboration agreement with AstraZeneca for the development of novel MALT1 inhibitors as therapeutics in inflammatory and oncological diseases.

31 Jan 2014

Vanda Pharmaceuticals announces FDA approval of HETLIOZ for Non-24 treatment

Vanda Pharmaceuticals Inc. today announced that the U.S. Food and Drug Administration has approved HETLIOZ (tasimelteon) 20mg capsules for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24). HETLIOZ is the first FDA approved medication for Non-24.

31 Jan 2014

Pharmaceutical News

Findings raise hope for new oral anticoagulants to treat patients with atrial fibrillation

Scientists engineered microchip coated with blood vessel cells to study cardiovascular nanomedicine

UCSF-led study gathers data on safety, tolerability of purified cannabinoid for children with epilepsy

95% of adults die annually from vaccine preventable diseases

New drug treatment effective against chronic pain caused by nerve damage post shingles

Researchers identify key step to prevent liver failure resulting from painkiller overdose

Blood disorder medicines could be used for treating stomach and bowel cancer

MORE intervention reduces pain and opioid misuse

Healthcare experts propose concrete steps for managing shortages of life-saving drugs

Edison's vatiquinone receives Orphan Status for treatment of Friedreich's ataxia

Discovery may have implications for HIV vaccine research

Patient controlled analgesia not equivalent to epidural analgesia for pain relief during labor

FDA grants Breakthrough Therapy designation to GSK's Promacta/Revolade for treatment of cytopenias

Addressing antibiotic resistance: an interview with Professor Otto Cars, Uppsala University, Sweden

Teen girls' beliefs regarding HPV vaccine not linked to subsequent sexual behaviors

Mylan launches trastuzumab biosimilar for treatment of HER2-positive metastatic breast cancer

Onset Dermatologics announces nationwide availability of Tretin-X Cream 0.075%

New study reveals way to combat drug-resistant tumors

VIB and CD3 sign agreement with AstraZeneca for development of novel MALT1 inhibitors

Vanda Pharmaceuticals announces FDA approval of HETLIOZ for Non-24 treatment

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest News